142 related articles for article (PubMed ID: 36179404)
1. Discovery of Pyrrolo[2,3-d]pyrimidine derivatives as potent and selective colony stimulating factor 1 receptor kinase inhibitors.
Liang X; Wang C; Wang B; Liu J; Qi S; Wang A; Liu Q; Deng M; Wang L; Liu J; Liu Q
Eur J Med Chem; 2022 Dec; 243():114782. PubMed ID: 36179404
[TBL] [Abstract][Full Text] [Related]
2. Identification of compound D2923 as a novel anti-tumor agent targeting CSF1R.
Liu YQ; Wang YN; Lu XY; Tong LJ; Li Y; Zhang T; Xun QJ; Feng F; Chen YZ; Su Y; Shen YY; Chen Y; Geng MY; Ding K; Li YL; Xie H; Ding J
Acta Pharmacol Sin; 2018 Nov; 39(11):1768-1776. PubMed ID: 29968849
[TBL] [Abstract][Full Text] [Related]
3. Design, Synthesis, and Structure-Activity Relationship Study of 2-Oxo-3,4-dihydropyrimido[4,5- d]pyrimidines as New Colony Stimulating Factor 1 Receptor (CSF1R) Kinase Inhibitors.
Xun Q; Zhang Z; Luo J; Tong L; Huang M; Wang Z; Zou J; Liu Y; Xu Y; Xie H; Tu ZC; Lu X; Ding K
J Med Chem; 2018 Mar; 61(6):2353-2371. PubMed ID: 29499108
[TBL] [Abstract][Full Text] [Related]
4. Colony-Stimulating Factor 1 Receptor (CSF1R) Activates AKT/mTOR Signaling and Promotes T-Cell Lymphoma Viability.
Murga-Zamalloa C; Rolland DCM; Polk A; Wolfe A; Dewar H; Chowdhury P; Onder O; Dewar R; Brown NA; Bailey NG; Inamdar K; Lim MS; Elenitoba-Johnson KSJ; Wilcox RA
Clin Cancer Res; 2020 Feb; 26(3):690-703. PubMed ID: 31636099
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological Properties of JTE-952, an Orally Available and Selective Colony Stimulating Factor 1 Receptor Kinase Inhibitor.
Uesato N; Miyagawa N; Inagaki K; Kakefuda R; Kitagawa Y; Matsuo Y; Yamaguchi T; Hata T; Ikegashira K; Matsushita M
Biol Pharm Bull; 2020; 43(2):325-333. PubMed ID: 32009119
[TBL] [Abstract][Full Text] [Related]
6. Dual inhibition of CSF1R and MAPK pathways using supramolecular nanoparticles enhances macrophage immunotherapy.
Ramesh A; Brouillard A; Kumar S; Nandi D; Kulkarni A
Biomaterials; 2020 Jan; 227():119559. PubMed ID: 31670078
[TBL] [Abstract][Full Text] [Related]
7. Discovery of IACS-9439, a Potent, Exquisitely Selective, and Orally Bioavailable Inhibitor of CSF1R.
Czako B; Marszalek JR; Burke JP; Mandal P; Leonard PG; Cross JB; Mseeh F; Jiang Y; Chang EQ; Suzuki E; Kovacs JJ; Feng N; Gera S; Harris AL; Liu Z; Mullinax RA; Pang J; Parker CA; Spencer ND; Yu SS; Wu Q; Tremblay MR; Mikule K; Wilcoxen K; Heffernan TP; Draetta GF; Jones P
J Med Chem; 2020 Sep; 63(17):9888-9911. PubMed ID: 32787110
[TBL] [Abstract][Full Text] [Related]
8. A highly selective purine-based inhibitor of CSF1R potently inhibits osteoclast differentiation.
Aarhus TI; Eickhoff J; Klebl B; Unger A; Boros J; Choidas A; Zischinsky ML; Wolowczyk C; Bjørkøy G; Sundby E; Hoff BH
Eur J Med Chem; 2023 Jul; 255():115344. PubMed ID: 37141705
[TBL] [Abstract][Full Text] [Related]
9. Discovery of potent colony-stimulating factor 1 receptor inhibitors by replacement of hinge-binder moieties.
Lee JW; Park J; Kim J; Kim J; Choi C; Min KH
Eur J Med Chem; 2021 Apr; 216():113298. PubMed ID: 33689933
[TBL] [Abstract][Full Text] [Related]
10. Reprofiling of pyrimidine-based DAPK1/CSF1R dual inhibitors: identification of 2,5-diamino-4-pyrimidinol derivatives as novel potential anticancer lead compounds.
Farag AK; Hassan AHE; Ahn BS; Park KD; Roh EJ
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):311-324. PubMed ID: 31809612
[TBL] [Abstract][Full Text] [Related]
11. The c.1085A>G Genetic Variant of
Yeh YM; Hsu SJ; Lin PC; Hsu KF; Wu PY; Su WC; Chang JY; Shen MR
Clin Cancer Res; 2017 Oct; 23(20):6021-6030. PubMed ID: 28724665
[No Abstract] [Full Text] [Related]
12. CSF1R inhibitors are emerging immunotherapeutic drugs for cancer treatment.
Wen J; Wang S; Guo R; Liu D
Eur J Med Chem; 2023 Jan; 245(Pt 1):114884. PubMed ID: 36335744
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and Development of Highly Selective Pyrrolo[2,3-
Aarhus TI; Bjørnstad F; Wolowczyk C; Larsen KU; Rognstad L; Leithaug T; Unger A; Habenberger P; Wolf A; Bjørkøy G; Pridans C; Eickhoff J; Klebl B; Hoff BH; Sundby E
J Med Chem; 2023 May; 66(10):6959-6980. PubMed ID: 37191268
[TBL] [Abstract][Full Text] [Related]
14. Antitumor activity of a pexidartinib bioisostere inhibiting CSF1 production and CSF1R kinase activity in human hepatocellular carcinoma.
Awasthi BP; Guragain D; Chaudhary P; Jee JG; Kim JA; Jeong BS
Chem Biol Interact; 2023 Jan; 369():110255. PubMed ID: 36368339
[TBL] [Abstract][Full Text] [Related]
15. Discovery of BPR1R024, an Orally Active and Selective CSF1R Inhibitor that Exhibits Antitumor and Immunomodulatory Activity in a Murine Colon Tumor Model.
Lee KH; Yen WC; Lin WH; Wang PC; Lai YL; Su YC; Chang CY; Wu CS; Huang YC; Yang CM; Chou LH; Yeh TK; Chen CT; Shih C; Hsieh HP
J Med Chem; 2021 Oct; 64(19):14477-14497. PubMed ID: 34606263
[TBL] [Abstract][Full Text] [Related]
16. Protein kinase A inhibition of macrophage maturation is accompanied by an increase in DNA methylation of the colony-stimulating factor 1 receptor gene.
Zasłona Z; Scruggs AM; Peters-Golden M; Huang SK
Immunology; 2016 Oct; 149(2):225-37. PubMed ID: 27353657
[TBL] [Abstract][Full Text] [Related]
17. CSF1/CSF1R signaling mediates malignant pleural effusion formation.
Kosti CN; Vaitsi PC; Pappas AG; Iliopoulou MP; Psarra KK; Magkouta SF; Kalomenidis IT
JCI Insight; 2022 Mar; 7(6):. PubMed ID: 35315360
[TBL] [Abstract][Full Text] [Related]
18. Rational combination of an immune checkpoint inhibitor with CSF1R inhibitor-loaded nanoparticle enhances anticancer efficacy.
Ramesh A; Malik V; Ranjani HA; Smith H; Kulkarni AA
Drug Deliv Transl Res; 2021 Dec; 11(6):2317-2327. PubMed ID: 34365577
[TBL] [Abstract][Full Text] [Related]
19. Targeting the CSF-1/CSF-1R Axis: Exploring the Potential of CSF1R Inhibitors in Neurodegenerative Diseases.
Baek J; Jun J; Kim H; Bae H; Park H; Cho H; Han S; Shin HC; Hah JM
J Med Chem; 2024 Apr; 67(7):5699-5720. PubMed ID: 38530425
[TBL] [Abstract][Full Text] [Related]
20. Early posttraumatic CSF1R inhibition via PLX3397 leads to time- and sex-dependent effects on inflammation and neuronal maintenance after traumatic brain injury in mice.
Wang Y; Wernersbach I; Strehle J; Li S; Appel D; Klein M; Ritter K; Hummel R; Tegeder I; Schäfer MKE
Brain Behav Immun; 2022 Nov; 106():49-66. PubMed ID: 35933030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
